Aadi Bioscience, INC Schedule 13G passive stakes

OrbiMed Advisors LLC and OrbiMed Genesis GP LLC have jointly reported beneficial ownership of 7.3% of Whitehawk Therapeutics, Inc. common stock as of June 30, 2026.

Coastlands Capital LP and its affiliates have reported a 5.98% beneficial ownership stake in Whitehawk Therapeutics, Inc. common stock.

OrbiMed Advisors LLC and OrbiMed Genesis GP LLC have jointly disclosed a passive beneficial ownership of 8.9% in Whitehawk Therapeutics, Inc., totaling 4,166,000 shares of common stock.

Point72 Asset Management and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 5,087 shares, representing 0% of Whitehawk Therapeutics, Inc.'s common stock.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have jointly disclosed beneficial ownership of up to 9.99% of Aadi Bioscience, Inc.'s common stock.

Ally Bridge Group and its affiliated entities, including Mr. Fan Yu, have filed a Schedule 13G disclosing their passive beneficial ownership of Aadi Bioscience, Inc. common stock, with Mr. Fan Yu holding an aggregate of 6.3%.

Muneer A. Satter has filed an amended Schedule 13G for Aadi Bioscience, Inc., indicating a beneficial ownership of 0% of the company's common stock as of December 31, 2024.

QVT Financial LP has reported a 9.37% beneficial ownership stake in Aadi Bioscience, Inc., holding 2,313,702 shares of common stock as of December 31, 2024.

EcoR1 Capital, LLC and its control person Oleg Nodelman, along with EcoR1 Capital Fund Qualified, L.P., have filed an amended Schedule 13G disclosing their beneficial ownership of 1.4% of Aadi Bioscience, Inc.'s common stock as of December 31, 2024.

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has disclosed a passive 6.0% beneficial ownership stake in Aadi Bioscience, Inc. through a Schedule 13G filing.